Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.63 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | GABRP | O00591 | 4/20 | 0.36 |
| ▸ | GABRD | O14764 | 4/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.36 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.36 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.36 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.36 |
| ▸ | GABRE | P78334 | 4/20 | 0.36 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2266575 | 1.00 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL83870 | 1.00 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL7335221 | 1.00 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL9135178 | 1.00 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL4330500 | 1.00 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| SCHEMBL87358 | 1.00 | SLC7A5 (0.63) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Hydrochloric Acid SCHEMBL7920996 | 0.97 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Hydrochloric Acid SCHEMBL7920991 | 0.97 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Hydrochloric Acid SCHEMBL9132421 | 0.97 | SLC7A5 (0.60) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 | |
| Sulfuric Acid SCHEMBL9403169 | 0.89 | SLC7A5 (0.52) | SLC7A5SLC1A3SLC1A2SLC1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230405091-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2023-12-21 | — | — | US | claimed |
| EP-4228424-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2023-08-23 | — | — | EP | claimed |
| CN-116390651-A | Methods of modulating gastrointestinal metabolites | 帝斯曼知识产权资产管理有限公司 | 2023-07-04 | — | — | CN | claimed |
| US-20230200412-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP ASSETS B.V. (NL) | 2023-06-29 | — | — | US | claimed |
| EP-4118090-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP Assets B.V. (NL) | 2023-01-18 | — | — | EP | claimed |
| CN-115551873-A | Methods for modulating gastrointestinal microbial metabolic pathways and metabolites | 帝斯曼知识产权资产管理有限公司 | 2022-12-30 | — | — | CN | claimed |
| WO-2022079238-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2022-04-21 | — | — | WO | claimed |
| CN-117740961-A | Compound analysis method of liquorice and liquorice probiotics fermentation preparation | 北京中医药大学 | 2024-03-22 | — | — | CN | disclosed |
| US-20230405091-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP ASSETS B.V. (NL) | 2023-12-21 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4228424-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2023-08-23 | — | — | EP | disclosed |
| CN-116390651-A | Methods of modulating gastrointestinal metabolites | 帝斯曼知识产权资产管理有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20230200412-A1 | METHODS OF MODULATING GASTROINTESTINAL MICROBIAL METABOLIC PATHWAYS AND METABOLITES | DSM IP ASSETS B.V. (NL) | 2023-06-29 | — | — | US | disclosed |
| US-7687492-B2 | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME CORP. (US) | 2010-03-30 | — | — | US | disclosed |
| EP-2084519-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | Los Alamos National Security, LLC (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008127291-A2 | ADVANCED DRUG DEVELOPMENT AND MANUFACTURING | LOS ALAMOS NATIONAL SECURITY, LLC (US) | 2008-10-23 | — | — | WO | disclosed |
| US-20080220441-A1 | Advanced drug development and manufacturing | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-09-11 | — | — | US | disclosed |
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | MERCK SHARP & DOHME LLC | 2008-01-24 | — | — | US | disclosed |
| EP-1756074-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005108382-A1 | 1,2,4-OXADIAZOLE DERIVATIVES AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021009-A1 | 1,2,4-Oxadiazole Derivatives as Dipeptidyl Peptidase-IV Inhibitors for the Treatment or Prevention of Diabetes | DPP4, DPP3, DPP7 | SLC7A5 3035/4885SLC1A3 1696/4885SLC1A2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.